A large-scale human toxicogenomics resource for drug-induced liver injury prediction.

Volker Bergen¹, Konstantia Kodella², Sreenath Srikrishnan², Ornella Barrandon², Sara Anderson², Max Rogers-Grazado², Casey Fowler², Hirit Beyene², Nicole Robichaud², Timothy Fulton², Nina Lapchyk², Mauricio Cortes², Nick Plugis², Matthew Goddeeris², Mahdi Zamanighomi³

¹Cellarity Inc., Somerville, MA, USA. DILImap@cellarity.com.

²Cellarity Inc., Somerville, MA, USA.

³Cellarity Inc., Somerville, MA, USA. mzamanighomi@cellarity.com.

PubMed PMC DOI PDF

Abstract

Drug-Induced Liver Injury (DILI) remains one of the most critical challenges in drug development, causing patient safety concerns, clinical trial failures and drug withdrawals. We introduce ToxPredictor, a toxicogenomics framework combining RNA-seq data from primary human hepatocytes with pharmacokinetic data to predict dose-resolved DILI risks and safety margins. At its core is DILImap, an RNA-se…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.